| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |